Ferring Pharmaceuticals

Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Managed Care, Oncology, General Health, Health, FDA, Clinical Trials, NMIBC, BCG, Toxicity, HG, Physician, Congress, Nadofaragene firadenovec, Survival, PD, Cystectomy, Ferring Pharmaceuticals, Patient, Aes, EAU, MD Anderson Cancer Center, University, Month, Carcinoma in situ, Safety, Division, Probability, CIS, Food, Pharmaceutical industry

“Intravesical gene therapy represents an important innovative treatment option for these patients.

Key Points: 
  • “Intravesical gene therapy represents an important innovative treatment option for these patients.
  • The efficacy analysis included 103 and 48 patients in the CIS and PD cohorts, respectively, who met the protocol definition of BCG-unresponsive NMIBC.
  • In total, 12.1% (13/107) and 20.0% (10/50) of patients in the CIS and PD cohorts, respectively, received ADSTILADRIN at three years.
  • In the CIS cohort, about 53% achieved a complete response (CR) at Month 3 in the primary analysis.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

Inception Fertility™ 2024 Annual Physician Summit: A Celebration of Collaboration, Patient Dedication, and Advancements in Fertility Research

Retrieved on: 
Thursday, March 14, 2024
Diamond, Health, Prelude, Organon, Learning, Merck Serono, Ferring Pharmaceuticals, Physician, Patient, Mental health, Patient experience, Reproductive medicine, Fertility, Labcorp, Inception, The Cooper Companies, Summit, Family, Parent, Nursing

HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.

Key Points: 
  • Global fertility leader's annual summit brings together physicians, team members across Inception's expansive family of brands
    HOUSTON, March 14, 2024 /PRNewswire/ -- Inception Fertility ™ (Inception), the largest provider of comprehensive fertility services in North America, held its Annual Inception Physician Summit in Nashville, Tennessee, February 22-25, 2024.
  • This included two full days of learning, team building, collaborating, and the field of reproductive medicine.
  • Panel sessions covered topics related to mental health in fertility care, groundbreaking research studies, and using technology to drive the patient and employee experience, among others.
  • The 2024 Patient Experience Awards included the Patient Experience Outstanding Practice Award, Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, and Patient Experience Tenet Leaders Awards.

Jungheinrich Selects Icertis to Drive Enterprise Transformation with Contract Intelligence

Retrieved on: 
Tuesday, February 27, 2024
Synovial joint, Icertis, ICI, Commerce, Risk, Referent, Mercedes-Benz, Lufthansa, CLM, Corporation, Ferring Pharmaceuticals

FRANKFURT, Germany, Feb. 27, 2024 /PRNewswire/ -- Icertis, the global leader in AI-powered contract intelligence company, today announced that Jungheinrich has selected Icertis Contract Intelligence (ICI) to modernize its contract processes. The seamless integration between SAP S/4HANA, SAP Subscription Billing, and the AI-powered, enterprise-grade platform from Icertis will enable Jungheinrich's team to accelerate negotiations by standardizing, automating, and streamlining contract management. The company will also leverage Icertis NegotiateAI to improve outcomes and mitigate risk by surfacing insights across high-volume contracts.

Key Points: 
  • FRANKFURT, Germany, Feb. 27, 2024 /PRNewswire/ -- Icertis , the global leader in AI-powered contract intelligence company, today announced that Jungheinrich has selected Icertis Contract Intelligence (ICI) to modernize its contract processes.
  • As a global provider of sustainable material handling products and intralogistics solutions, Jungheinrich is undergoing an enterprise-wide digital transformation.
  • "Icertis Contract Intelligence gives us a holistic view of the contract lifecycle and streamlines our contract creation process for optimal outcomes."
  • As the leader of the burgeoning $30 billion CLM market 1, Icertis introduced the first generative AI Copilots for enterprise contract management and continues to transform the foundation of commerce through contracts for customers like Jungheinrich.

Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance

Retrieved on: 
Wednesday, February 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Ketan, University of the Sciences, Windtree Therapeutics, Pharma, Growth, Knowledge, Attention deficit hyperactivity disorder, CGMP, Good manufacturing practice, Therapy, Patient, Pain, SCA, Ferring Pharmaceuticals, ADHD, DSM-IV codes, Drug development, Addiction, Johnson & Johnson

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.
  • Mr. Magee will lead and further strengthen Tris Pharma’s continued development and management of quality and compliance operations via the current Good Manufacturing Practices (cGMP) Compliance function of the organization.
  • “Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” said Nicholas Cappuccino, Ph.D., chief quality officer, senior vice president of quality & compliance at Tris Pharma.
  • “I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”

Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting

Retrieved on: 
Wednesday, January 24, 2024
Research, FDA, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Oncology, Ageing, RWE, Mortality, Carcinoma in situ, Patient, PST, Progression-free survival, Ferring Pharmaceuticals, ASCO, CIS, EQ-5D, BCG, University, Society, Urinary bladder, Recurrence, Food, Carcinoma, Safety, Work, Disease, Bladder cancer, Doctor of Health Science, Progress, Real, Clinical trial, NMIBC, Physician, Pharmaceutical industry

ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness, overall experiences, patterns of use, and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in a U.S. real-world setting.

Key Points: 
  • ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness, overall experiences, patterns of use, and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in a U.S. real-world setting.
  • “I am thrilled to be part of this ongoing research and among the first uro-oncologists to be treating patients with ADSTILADRIN in a clinical setting.
  • Final results from this prospective, multi-institutional study are expected at the end of 2026.
  • Trials in Progress Poster Session B: Urothelial Carcinoma
    Abstract #TPS705, Friday, Jan. 26 at 5:45 - 6:45 p.m. PST

Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Managed Care, General Health, Clinical Trials, Pharmaceutical, Biotechnology, RWE, Senior, Carcinoma in situ, Patient, Bladder cancer, Ferring Pharmaceuticals, CIS, BCG, Urinary bladder, BCAN, Investment, FDA, NMIBC, Bacillus, Pharmaceutical industry

Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.

Key Points: 
  • Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.
  • “With our significant manufacturing investments, we have achieved full product supply ahead of schedule.
  • Now that full product supply is available ahead of schedule, Ferring can end the temporary ADSTILADRIN Early Experience Program and dramatically increase patient access.
  • This ongoing study is exploring early utilization, experiences, and outcomes of ADSTILADRIN in the routine care setting.

Stephanie Schull, PhD, CEO of Kegelbell, acknowledged as a trailblazing leader in women's health and FemTech for two consecutive years

Retrieved on: 
Wednesday, December 20, 2023
Doctor, Women's health, Kate Ryder, Woman, Ferring Pharmaceuticals, FDA, Health, Doctor of Philosophy, Femtech, Creativity

MESA, Ariz., Dec. 20, 2023 /PRNewswire-PRWeb/ -- Stephanie Schull, PhD, the visionary CEO of Kegelbell, has been honored for her exceptional leadership and innovation in the Women's Health and FemTech sectors for the second consecutive year. Recognized among the top 200 Trailblazing Leaders in Women's Health and FemTech for both 2022 and 2023, Stephanie Schull stands out as one of only 60 leaders to achieve this remarkable distinction two years in a row.

Key Points: 
  • "It is an honor to be recognized alongside such accomplished and dedicated leaders in Women's Health and FemTech.
  • At Kegelbell, we remain committed to pushing boundaries and developing solutions that positively impact the lives and health of women globally."
  • The prestigious list, compiled and documented by industry experts Anja Streicher and Marija Butkovic, features influential figures who have significantly contributed to advancing women's health and FemTech.
  • Stephanie Schull's inclusion on the list for two consecutive years underscores her sustained excellence and leadership in the industry.

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Retrieved on: 
Monday, December 11, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Ferring Pharmaceuticals, Disease, Therapy, Multimedia, Patient, Dysbiosis, Microbiome, Gastroenterology, Senior, FDA, Antibiotics, Pharmaceutical industry, Ferring

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

Key Points: 
  • Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
  • View the full release here: https://www.businesswire.com/news/home/20231210383233/en/
    The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
  • “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients.
  • PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals.

New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)

Retrieved on: 
Wednesday, November 29, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, BCG, Vice, Safety, Food, NMIBC, Toxicity, Carcinoma in situ, Carcinoma, Clinical trial, HG, Patient, Probability, Ferring Pharmaceuticals, CIS, Cystectomy, Mayo Clinic, EST, Recurrence, SUO, Society, HIV disease progression rates, Pharmaceutical industry

ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.

Key Points: 
  • ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.
  • Patients without evidence of HG recurrence were allowed to continue ADSTILADRIN treatment every three months as part of an ongoing follow-up analysis.
  • Among patients who continued treatment after the 12-month Phase 3 period, 25.5% (14/55 patients) remained HG recurrence-free at 36 months following the start of treatment.
  • At 36 months, the KM-estimated cystectomy-free survival (95% CI) was 53.8% (43.3%, 63.1%), and the three-year overall survival was 90.4% (82.3%, 94.9%).